ArticleBiotechnology and bioengineering2026
Spray-Dried Engineered Escherichia coli Whole-Cell Biocatalysts Enable Cell Recycling and In Vivo α-Ketoglutarate and NADPH Regeneration for Efficient Codeine Manufacture.
Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A recombinant whole-cell biocatalytic approach provides several advantages over isolated enzymes, such as improved enzyme stability, in vivo cofactor regeneration, and the facilitation of cascade reactions within a single cell. Whole-cell biocatalysis has gained attention in medicinal opioid production, due to its technical and economic advantages. In this study, recombinant Escherichia coli producing thebaine 6-O-demethylase (T6ODM), neopinone isomerase (NISO), and codeinone reductase (COR) were used to convert thebaine into codeine. Spray-drying was developed to optimize enzymatic activity in dried biocatalytic cells, achieving over 85% enzyme activity retention. These formulated cells were evaluated over multiple recycled reaction cycles that relied on in vivo cofactor regeneration. The native enzyme isocitrate dehydrogenase (IDH) regenerated both α-ketoglutarate and NADPH, critical for T6ODM and COR activity, respectively. The biocatalysts demonstrated high durability across 10 reaction cycles, with IDH and COR maintaining consistent activity. However, T6ODM exhibited a 40% reduction in activity, aligning with its lower thermal stability. The two-step bioconversion process yielded an average 68% molar yield of codeine after 10 cycles, with full thebaine consumption, demonstrating efficient cofactor and co-substrate recycling without further cellular engineering. This study highlights the potential of spray-dried E. coli cells as a sustainable and scalable approach for codeine biomanufacturing from thebaine. These results provide a strong foundation for further industrial application, offering both economic and technical benefits for large-scale opioid production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.